FUSEN PHARM(01652.HK): Peramivir Injection Granted Marketing Approval; Domestic Market Size Exceeded RMB800 Million in 2025

NewTimeSpace News: Fusen Pharmaceutical Company Limited (01652.HK) issued a voluntary announcement on 26 June 2026, disclosing that the New Drug Application for Peramivir Injection developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has obtained marketing approval from the National Medical Products Administration (NMPA).

Peramivir Injection is the only injectable anti-influenza agent approved by the US FDA, as well as the first neuraminidase inhibitor approved in China for intravenous administration against influenza A and B. It is suitable for severe influenza patients and those unable to take oral oseltamivir, delivering rapid fever reduction and relief from influenza symptoms including nasal congestion, rhinorrhea, expectoration and cough. Peramivir selectively inhibits neuraminidase of human influenza A and B viruses, blocking the release of mature virions from host cells to exert therapeutic effects, and is indicated for patients of all age groups infected with influenza A or B.

Classified as a Class B National Medical Insurance drug, this product is recommended in multiple clinical guidelines and consensus documents such as theInfluenza Diagnosis and Treatment Protocoland theClinical Practice Guidelines for Diagnosis and Treatment of Common Cold in Adults. According to data from Menet, total sales of peramivir formulations across China’s three major medical terminals and six core markets exceeded RMB800 million in 2025.